



US009511068B2

(12) **United States Patent**
Suh et al.

(10) **Patent No.:** **US 9,511,068 B2**
(45) **Date of Patent:** **Dec. 6, 2016**

(54) **COMPOSITION FOR TREATING OR PREVENTING DISEASES CAUSED BY VASCULAR PERMEABILITY, CONTAINING IMATINIB OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS ACTIVE INGREDIENT**

2009/0325977 A1 12/2009 Wedge
2010/0069398 A1 3/2010 Wedge
2010/0190800 A1 7/2010 Alland et al.
2012/0295917 A1 11/2012 Kim et al.

FOREIGN PATENT DOCUMENTS

(71) Applicant: **AJOU UNIVERSITY INDUSTRY - ACADEMIC COOPERATION FOUNDATION**, Suwon-si, Gyeonggi-do (KR)

CN 101027059 A 8/2007
CN 101594851 A 12/2009
RU 2009148985 A 8/2011
WO 2005020972 A2 3/2005
WO 2006/035204 A2 4/2006
WO 2006035203 A1 4/2006
WO 2006035204 A2 4/2006
WO 2008/055965 A1 5/2008
WO 2008/055966 A1 5/2008
WO 2008/154262 A1 12/2008
WO 2010139678 A1 12/2010

(72) Inventors: **Won Hee Suh**, Seongnam-si (KR); **Ji Yeon Kim**, Suwon-si (KR)

(73) Assignees: **Ajou University Industry-Academic**, Suwon-si, Gyeonggi-do (KR); **Cooperation Foundation** (KR)

OTHER PUBLICATIONS

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

Grunwald et al., "Chronic Myelogenous Leukemia and Retinopathy Treated with Imatinib", *Retinal Cases & Brief Reports*, 5:366-368 (2011).

(21) Appl. No.: **14/409,441**

Deininger et al., "Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib", *Pharmacological Reviews*, 55(3):401-423 (2003).

(22) PCT Filed: **Jun. 10, 2013**

European Search Report for corresponding European Application No. 13807815.9, dated Jan. 5, 2016.

(86) PCT No.: **PCT/KR2013/005068**

§ 371 (c)(1),

(2) Date: **Dec. 18, 2014**

Dafni et al., "Macromolecular Dynamic Contrast-Enhanced (DCE)-MRI Detects Reduced Vascular Permeability in a Prostate Cancer Bone Metastasis Model Following Anti-Platelet-Derived Growth Factor Receptor (PDGFR) Therapy, Indicating a Drop in Vascular Endothelial Growth Factor Receptor (VEGFR) Activation", *Magnetic Resonance in Medicine*, 60:822-833 (2008).

(87) PCT Pub. No.: **WO2013/191401**

PCT Pub. Date: **Dec. 27, 2013**

Aman et al., "The Anticancer Drug Imatinib Protects Against Endothelial Barrier Dysfunction", *Regulators of the Lung Endothelial Barrier*, *American J. Resp. Crit. Care Med.*, 183(1) Supp. (2011).

(65) **Prior Publication Data**

US 2015/0320750 A1 Nov. 12, 2015

Japanese Office Action for Japanese application counterpart No. 2015112601248000, dated Dec. 1, 2015.

(30) **Foreign Application Priority Data**

Jun. 18, 2012 (KR) 10-2012-0065193

Russian Office Action for Russian application counterpart No. 201415382/15 (082265), dated Mar. 1, 2016.

(51) **Int. Cl.**

A61K 31/506 (2006.01)

C07D 401/04 (2006.01)

Primary Examiner — Michael Barker

(74) *Attorney, Agent, or Firm* — McDonnell Boehnen Hulbert & Berghoff LLP

(52) **U.S. Cl.**

CPC **A61K 31/506** (2013.01); **C07D 401/04** (2013.01)

(57) **ABSTRACT**

(58) **Field of Classification Search**

None
See application file for complete search history.

The present invention relates to a pharmaceutical composition for treating or preventing diseases caused by vascular permeability, containing imatinib, which has been conventionally used as an agent for treating chronic myeloid leukemia, or a pharmaceutically acceptable salt thereof as an active ingredient, and a method for treating disease caused by vascular permeability using the composition. The pharmaceutical composition for treating or preventing diseases caused by vascular permeability of the present invention contains imatinib, which has been conventionally used as an agent for treating chronic myeloid leukemia, as an active ingredient, so as to provide a novel use of imatinib and to be able to effectively treat or prevent diseases caused by vascular permeability, and thus may be widely applied to develop a novel agent for treating diseases caused by vascular permeability.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,521,184 A 5/1996 Zimmermann
7,767,688 B2 8/2010 Alland et al.
8,293,745 B2 10/2012 Riviere et al.
2005/0203013 A1 9/2005 Soker et al.
2006/0275260 A1 12/2006 Riviere et al.
2008/0003219 A1 1/2008 Peyman
2008/0015205 A1 1/2008 Wedge
2008/0119479 A1 5/2008 Wedge
2008/0312252 A1 12/2008 Alland et al.